Related Experiment Video
Updated: Dec 24, 2025
06:04
Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
Published on: August 8, 2025
446
Novel Perspective for Antithrombotic Therapy in TAVI.
Maria Drakopoulou1, Stergios Soulaidopoulos1, George Oikonomou1
1First Department of Cardiology, Hippokration Hospital, Medical School of Athens University, Athens, Greece.
Current Pharmaceutical Design
|April 14, 2020
Summary
Transcatheter aortic valve implantation (TAVI) has transformed aortic stenosis treatment, expanding to lower-risk patients. Optimal antithrombotic therapy post-TAVI is vital but requires further research on combinations and duration.
Area of Science:
- Cardiology
- Interventional Cardiology
- Vascular Medicine
Background:
- Surgical aortic valve replacement (SAVR) was the standard for aortic stenosis.
- Transcatheter aortic valve implantation (TAVI) emerged in 2002, revolutionizing treatment approaches.
- TAVI indications have broadened to include lower surgical risk populations.
Purpose of the Study:
- To review pathogenetic mechanisms of TAVI thrombotic complications.
- To evaluate current antithrombotic strategies after TAVI based on randomized trials.
- To address the scarcity of evidence on optimal antithrombotic therapy post-TAVI.
Main Methods:
- Literature review of randomized controlled trials.
- Analysis of pathogenetic mechanisms of thrombotic complications.
- Evaluation of antithrombotic policies and their efficacy.
Main Results:
- TAVI has become a primary treatment option for symptomatic aortic stenosis.
- Antithrombotic therapy is critical for preventing complications and improving survival post-TAVI.
- Limited randomized trials exist for optimal antithrombotic strategies post-TAVI.
Conclusions:
- TAVI represents a significant advancement in aortic stenosis management.
- Effective antithrombotic therapy is essential for TAVI success.
- Further research is needed to define optimal antithrombotic regimens after TAVI.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.9K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.9K
01:29Venous Thrombosis III: Interprofessional Care
217
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
217
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
967
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
967
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
380
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
380
01:30Venous Thrombosis IV: Nursing Management
153
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
153
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.5K